CCR2 and familial pancreatic carcinoma: Using a comparable strategy to improve pancreatic cancer outcomes was not as clear-cut, when Noel and colleagues used a different type of small molecule antagonist inhibitor of CCR2, under a phase 1b study of combined treatment with nab-paclitaxel/gemcitabine in metastatic pancreatic cancer patients.